PALISADE BIO INC (PALI) Stock News

USA - Nasdaq - NASDAQ:PALI - US6963894026 - Common Stock

1.67 USD

-0.01 (-0.6%)

Last: 12/18/2025, 8:00:02 PM

1.74 USD

+0.07 (+4.19%)

Pre-Market: 12/19/2025, 6:22:35 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PALI Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Palisade Bio, Inc.

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

24 days ago - By: Palisade Bio, Inc.

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

a month ago - By: Zacks Investment Research

Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher

a month ago - By: Zacks Investment Research

All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

2 months ago - By: Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)

3 months ago - By: Stocktwits

News Image

Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

2 months ago - By: Benzinga

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

2 months ago - By: Benzinga - Mentions: IONR DFLI CRML AIP ...

Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

4 months ago - By: Palisade Bio, Inc.

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108